Summit Therapeutics (SMMT) on Sunday said ivonescimab significantly extended survival compared with Merck’s (MRK) Keytruda in ...
Akeso and Summit Therapeutics’ ivonescimab reduced the risk of death by 27% compared with Keytruda in patients with treatment ...
CAMBRIDGE, United Kingdom, April 29, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic ...
Investor's Business Daily on MSN
Summit packs a punch for Merck's Keytruda — but not everyone is sold
Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda.
Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a ...
Keytruda is a prescription drug that’s given as an intravenous (IV) infusion (and injection into a vein over a period of time). Learn about how the drug is given, how often you’ll receive doses, and ...
Merck receives positive EU CHMP opinion for Keytruda plus Padcev as perioperative treatment for adults with resectable MIBC: Rahway, New Jersey Saturday, September 19, 2026, 11:00 ...
NOW PLAYING The Cell Therapy Market Is Expected To Grow 600% Over The Next Decade. This Biotech Is Poised To Capitalize On That Wave. In a presentation at the World Conference on Lung Cancer, Summit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results